

Sale of Agrochemicals Business Investor Presentation

Melbourne, Australia; 14 June 2017: Starpharma Holdings Limited (ASX: SPL, OTCQX: SPHRY), will be holding an investor conference call today at 11am (AEST) to discuss the sale of its Agrochemicals business to Agrium Inc., for \$35 million. A presentation featuring further information on the transaction is attached.

Investor Conference Call:

An investor conference call will be conducted at 11:00am (AEST) today to discuss the sale of Starpharma Agrochemicals.

 Melbourne/Sydney (Aust), Wednesday 14th, 11am (AEST)
 1 800 558 698

 San Francisco (US), Tuesday 13th, 6pm (PDT)
 (855) 881 1339

 New York (US), Tuesday 13th, 9pm (EDT)
 (855) 881 1339

 London (UK), Wednesday 14th, 2am (BST)
 0800 051 8245

 Hong Kong, Wednesday 14th, 9am (HKT)
 800 966 806

 Singapore, Wednesday 14th, 9am (SGT)
 800 101 2785

Please quote conference ID: 258440

To register please go to <u>https://services.choruscall.com.au/diamondpass/buchan-258440-</u>invite.html

ABOUT STARPHARMA

Starpharma Holdings Limited (ASX: SPL, OTCQX:SPHRY), located in Melbourne Australia, is an ASX 300 company and is a world leader in the development of dendrimer products for pharmaceutical, life science and other applications.

Starpharma's underlying technology is built around dendrimers – a type of synthetic nanoscale polymer that is highly regular in size and structure and well suited to pharmaceutical and medical uses. Starpharma has two core development programs: VivaGel® portfolio and DEP® drug delivery with the Company developing a number of products internally and others via commercial partnerships.

Starpharma's portfolio includes late stage women's health products based on VivaGel[®] (SPL7013, astodrimer sodium), a proprietary dendrimer. VivaGel[®] formulated as a water based gel and delivered vaginally - VivaGel[®] BV - has EU regulatory approval for topical treatment and rapid relief of bacterial vaginosis (BV) and is also under clinical development for the prevention of recurrent BV. Starpharma has signed a license agreement with Aspen Pharmacare Australia Pty Ltd for the sales and marketing of VivaGel[®] BV in Australia and New Zealand. Starpharma has also signed separate license agreements with Ansell Limited (ASX:ANN), Okamoto Industries. Inc., (TSE: JP3192800005), Sky and Land (China) and Koushan Pharmed (Iran) to market a value-added, VivaGel[®] condom. The VivaGel[®] condom is available for purchase in Australia and in Canada under Ansell's Lifestyles[®] Dual Protect[™] brand. Ansell manufactures and sells leading condom brands worldwide, including LifeStyles[®], Manix[®], ZERO[®] and SKYN[®]. Okamoto is the market leader for condoms sold in Japan, which is the world's second largest condom market.

The other major part of Starpharma's pharmaceuticals business is its proprietary DEP® drug delivery platform. Starpharma has both partnered and internal DEP® programs in Drug Delivery. A number of dendrimer-enhanced, or DEP® versions of existing drugs are under development by the Company. The most advanced of these is DEP® docetaxel, a dendrimer-enhanced version of docetaxel (Taxotere®), which is in clinical development in patients with solid tumours. In preclinical studies DEP® docetaxel has shown significant tumour-targeting and superior anti-cancer effects across a range of important

cancer types including breast, prostate, lung and ovarian tumour, when compared to Taxotere® (docetaxel). In the partnered area, AstraZeneca has signed a licensing agreement with Starpharma for the use of its DEP® drug delivery platform in the development and commercialisation of a number of AstraZeneca oncology compounds.

For more information please visit: www.starpharma.com

FOR FURTHER INFORMATION

Media:

WE Buchan Consulting Rebecca Wilson Mob: +61 417 382 391 rwilson@buchanwe.com.au

Arthur Chan +61 2 9237 2805 achan@buchanwe.com.au Starpharma:

Dr Jackie Fairley, Chief Executive Officer Nigel Baade, CFO and Company Secretary

+61 3 8532 2704 investor.relations@starpharma.com www.starpharma.com

Forward Looking Statements

This document contains certain forward-looking statements, relating to Starpharma's business, which can be identified by the use of forward-looking terminology such as "promising", "plans", "anticipated", "will", "project", "believe", "forecast", "expected", "estimated", "targeting", "aiming", "set to", "potential", "seeking to", "goal", "could provide", "intends", "is being developed", "could be", "on track", or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA's and other authorities' requirements regarding any one or more product candidates nor can there be any assurance that such product candidates will be approved by any authorities for sale in any market or that they will reach any particular level of sales. In particular, management's expectations regarding the approval and commercialization of the product candidates could be affected by, among other things, unexpected trial results, including additional analysis of existing data, and new data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. Starpharma is providing this information as of the date of this document and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.



Sale of Starpharma Agrochemicals to Agrium Inc.

June 2017



starpharma

This document contains certain forward-looking statements, relating to Starpharma's business, which can be identified by the use of forward-looking terminology such as "promising", "plans", "anticipated", "will", "project", "believe", "forecast", "expected", "estimated", "targeting", "aiming", "set to", "potential", "seeking to", "goal", "could provide", "intends", "is being developed", "could be", "on track", or similar expressions, or by express or implied discussion regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA's and other authorities' requirements regarding any one or more product candidates nor can there be any assurance that such product candidates will be approved by any authorities for sale in any market or that they will reach any particular level of sales. In particular, management's expectations regarding the approval and commercialisation of the product candidates could be affected by, among other things, unexpected trial results, including additional analysis of existing data, and new data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry and general public pricing pressure; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospectus. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. Starpharma is providing this information as of the date of this document and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.


Sale of Starpharma Agrochemicals

Amount	A\$35M in cash consideration
Purchaser	 Agrium Inc. (NYSE:AGU, TSE: AGU) Market Cap ~US\$13B Annual revenues ~ US\$14B p.a. Global reach: 1,500 Ag-retail outlets and 15,200 staff
Portfolio sold	 Starpharma Agrochemicals comprises key Priostar[®] patents and know-how, and a small number of staff dedicated solely to agrochemicals Sale has no impact on VivaGel[®] or DEP[®] IP
Strategic rationale	 Planned strategy to maximise the value of, and monetise Priostar[®] IP/technology Enables Starpharma to focus on core pharmaceutical portfolios Significantly strengthens SPL's balance sheet; cash will be re-invested into high-value pharmaceutical programs, including DEP[®]
Financial impact	 >\$60M cash balance estimated at 30 June 2017 Sale amount is 4x book value of A\$7.5M No income tax payable Reduces associated R&D expenditure
Timing	No conditions precedent - transaction signed and completed
Sale process	Global process conducted by Starpharma and advisers, Macquarie Capital

starpharma

Agrium: A global leader in Agricultural Products







"This acquisition represents an exciting strategic technology platform for Loveland Products that will serve to further differentiate our proprietary product line and open new product development partnership opportunities.


Agrium is uniquely positioned to commercialize this technology across our 1,500 ag-retail centers, which service hundreds of thousands of growers in key agricultural markets globally"




Chuck Magro, President & CEO of Agrium

Transaction completed for \$35M cash





Pre-transaction: Starpharma's portfolio




CORE PHARMACEUTICAL PORTFOLIOS

starpharma

Post-transaction: Starpharma's portfolio



- The transaction focuses Starpharma's strategy on maximising the potential of its core pharmaceutical programs VivaGel[®] and DEP[®]
- Transaction has no impact on VivaGel® or DEP® IP



>\$60M cash balance enables Starpharma to:

- Expedite development of DEP[®] candidates
- Broaden DEP[®] programs run more clinical trials in parallel
- Accelerate commencement of new clinical programs
- Explore other related pharma opportunities

VivaGel[®] and DEP[®]: Significant Market Opportunities



VivaGel[®] Portfolio

- BV treatment market est. >US\$750M
- BV prevention market est. >US\$1B
- Branded global condom market in excess of US\$1B

C Returns through licensing agreements

- Milestones
- Royalties
- Product Margin

□ Three high value products

Global commercial deal process for additional licenses

DEP[®] Drug Delivery Portfolio

AstraZeneca deal:

- first product est. US\$450M (US\$126M + royalties)
- subsequent products US\$93M + royalties
- Taxotere® (Docetaxel) sales US\$3.1B
- Jevtana[®] (Cabazitaxel) sales US\$426M
- Campostar® (Irinotecan) sales US\$1.1B
- Targeted DEP[®] partnerships and programs

Platform with broad optionality

Internal

- Returns through licensing after "mid-phase" clinical trials (eg. DEP[®] docetaxel)
- Milestones and Royalties

Partnered

- Returns through funded development
- Milestones and Royalties (eg. AstraZeneca)



Starpharma:

Dr Jackie Fairley, Chief Executive Officer Nigel Baade, CFO and Company Secretary

+61 3 8532 2704 investor.relations@starpharma.com www.starpharma.com Media: WE Buchan Consulting Rebecca Wilson Mob: +61 417 382 391 rwilson@buchanwe.com.au